Lille (France), Cambridge (Massachusetts,
USA), Zurich (Switzerland), April 25, 2024 -
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company committed to improving the lives of
patients with rare, life-threatening liver diseases, today
announced the publication of its 2024 Extra-Financial Performance
Report (fiscal year 2023).
Third edition of the Extra-Financial
Performance report
Since 2022, GENFIT has published a detailed
Extra-Financial Performance report in response to the growing
interest of institutional and individual shareholders, financial
analysts, analysts specializing in corporate social responsibility
(CSR) issues, company employees and candidates wishing to join the
Company, industrial and strategic partners, and public
institutions. The Company is also preparing for the application of
new or draft European standards relating to non-financial
disclosures.1 The 2024 report (fiscal year 2023) is available on
GENFIT's website.
Pascal Prigent, Chief Executive Officer
of GENFIT, commented:
"GENFIT's commitment to the principles of social
responsibility is more than a question of ethics, it's a conviction
deeply rooted in our corporate culture. The ESG Committee,
established by our Board of Directors in 2021, monitors an annual
action plan that clearly defines our ambition through the
implementation of tangible initiatives, the adoption of engaging
policies and the tracking of performance indicators aligned with
our key issues. The implementation of our CSR strategy is a
priority that is regularly monitored by the Executive Committee.
Through our first double materiality analysis formally conducted
with Euronext Corporate Services at the end of 2023, we have not
only strengthened our engagement with our stakeholders, but we have
also begun laying the foundation for our future disclosure
requirements under the European Corporate
Sustainability Reporting Directive, which will be
applicable to us a few years down the line."
2023 review and 2024 outlook
The work in CSR carried out by GENFIT and its transparency in
its communications since 2021 have, again, been recognized this
year by the independent rating agencies, which acknowledged our
significant progress in terms of extra-financial performance, with
a gold medal awarded by Ethifinance (Gaïa report) in 2023, a "Prime
C+" status granted by ISS and a "best-in-class" classification by
ODDO Research. GENFIT counts among its shareholders a social impact
fund, classified as Article 9 under the European SFDR (Sustainable
Finance Disclosure Regulation). This social impact fund has been
awarded the "Relance" label and is a candidate for the "Socially
Responsible Investment" label. Lastly, GENFIT was selected in the
"Governance" category by the LEEM (Les Entreprises du Médicament)
as part of its CSR awards.
Regarding our ambitious 2023 roadmap, we have successfully
executed this in alignment with the plan crafted by the ESG
Committee. The 2024 roadmap seamlessly extends this strategic
direction.
ABOUT OUR CSR COMMITMENT
Our commitment is driven, above all, from our determination to
act as a socially responsible company. As a biopharmaceutical
company, this commitment goes beyond our core activity whose
purpose it is to respond to the societal need of developing
innovative, effective and safe therapeutic solutions for patients
suffering from rare and severe liver diseases with a high unmet
medical need. This is aligned with the third Sustainable
Development Goal of the United Nations.
GENFIT recognizes that there is a correlation between its
long-term financial performance and its extra-financial performance
in that the societal impact of its research and development
programs, as well as its rigorous governance practices
(particularly in relation to the demands of the relevant health
authorities and financial market regulators), the social impact of
its activity, and its low environmental footprint, could create
meaningful long-term value for patients, healthcare systems,
employees and shareholders, and assure the Company’s growth and
long-term future.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
committed to improving the lives of patients with rare,
life-threatening liver diseases whose medical needs remain largely
unmet. GENFIT is a pioneer in liver disease research and
development with a rich history and a solid scientific heritage
spanning more than two decades. Today, GENFIT has built up a
diversified and rapidly expanding R&D portfolio of programs at
various stages of development. The Company focuses on
Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes
five assets under development: VS-01, NTZ, SRT-015, CLM-022 and
VS-02-HE, based on complementary mechanisms of action using
different routes of administration. Other active ingredients target
other serious diseases, such as cholangiocarcinoma (CCA), urea
cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise
in the development of high-potential molecules from early to
advanced stages, and in pre-commercialization, was demonstrated
with the success of the 52-week Phase 3 ELATIVE® study evaluating
elafibranor in Primary Biliary Cholangitis (PBC). Beyond therapies,
GENFIT also has a diagnostic franchise including NIS2+® in
Metabolic dysfunction-associated steatohepatitis (MASH, formerly
known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing
on blood ammonia levels. GENFIT is headquartered in Lille, France
and has offices in Paris (France), Zurich (Switzerland) and
Cambridge, MA (USA). The Company is listed on the Nasdaq Global
Select Market and on the Euronext regulated market in Paris,
Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became
one of GENFIT's largest shareholders, acquiring an 8% stake in the
Company's capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains forward-looking
statements about GENFIT, including within the meaning of the
Private Securities Litigation Reform Act of 1995. The use of
certain words, such as "believe", "potential", "expect", "should",
"could", "if" and similar expressions, is intended to identify
these forward-looking statements. Although the Company believes
that its projections are based on management's reasonable
assumptions and expectations, such forward-looking statements may
be affected by a number of known and unknown risks and
uncertainties, which could cause actual results to differ
materially from those described in, or implied or projected by,
such forward-looking statements. These contingencies and
uncertainties include, among others, the uncertainties inherent in
research and development and GENFIT’s extra-financial performance.
These hazards and uncertainties also include those discussed in
chapter 2 "Risk Factors and Internal Control" of the Company's 2023
Universal Registration Document filed on April 5, 2024 (no.
D.24-0246) with the Autorité des marchés financiers ("AMF"), which
is available on GENFIT's website (www.genfit.fr) and the AMF's
website (www.amf.org), and those discussed in the public documents
and reports filed with the U.S. Securities and Exchange Commission
("SEC"), including the Form 20-F filed with the SEC on the same
date. Moreover, even if the results, performance, financial
position and liquidity of the Company and the development of the
industry sector in which it operates are in line with such
forward-looking statements, they cannot be predictive of future
results or developments. These forward-looking statements speak
only as of the date of publication of this document. Subject to
applicable regulations, the Company undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
otherwise.
CONTACT
GENFIT | Investors
Investor Relations | Tel : +33 3 20 16 40 00 |
investors@genfit.com
PRESS RELATIONS | Media
Bruno ARABIAN - Ulysse Communication | Tel : 06
87 88 47 26 | barabian@ulysse-communication.com
Stephanie BOYER - GENFIT | Tel : 03 20 16 40 00
| stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos -
FRANCE | +333 2016 4000 | www.genfit.com
1. Corporate Sustainability Reporting Directive (CSRD)
- GENFIT: Publication of the 2024 Extra-Financial Performance
Report (fiscal year 2023)
Genfit (EU:GNFT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Genfit (EU:GNFT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
